Giancarlo Castaman

Q: What Schools Are Affiliated With Giancarlo Castaman

Giancarlo Castaman is affiliated with the following schools: University of California, Berkeley, University of Milan, Tel Aviv University, Stanford University, Yamagata University, University of Florence, University of Bologna

Giancarlo Castaman's AcademicInfluence.com Rankings

Giancarlo Castaman

Physics

#6096

World Rank

#8001

Historical Rank

physics Degrees

Download Badge

Physics

Giancarlo Castaman's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Giancarlo Castaman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giancarlo Castaman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Epidemiological investigation of the prevalence of von Willebrand's disease. (1987) (942)
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) (2006) (509)
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). (2007) (384)
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study (2005) (324)
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. (2009) (240)
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. (1990) (234)
Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis (2001) (229)
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. (2003) (210)
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. (2018) (207)
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. (2008) (192)
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. (2013) (189)
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. (1997) (173)
Detection of New Polymorphic Markers in the Factor V Gene: Association with Factor V Levels in Plasma (1996) (171)
Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. (1998) (169)
Principles of care for the diagnosis and treatment of von Willebrand disease (2013) (166)
Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) (2008) (160)
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). (2008) (159)
Guidelines for the diagnosis and management of von Willebrand disease in Italy (2002) (152)
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. (2016) (149)
The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. (2000) (140)
Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. (1996) (137)
Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia (2000) (130)
Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. (1992) (129)
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients (2012) (123)
von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. (1988) (119)
Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation (2011) (119)
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (2006) (117)
Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. (2015) (116)
Thrombosis during Pregnancy and Surgery in Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (116)
The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. (2014) (116)
von Willebrand factor regulation of blood vessel formation. (2018) (111)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. (2008) (110)
von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery (2007) (109)
Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update (2013) (104)
Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation (1999) (103)
Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin (1998) (102)
Cysteine‐mutations in von Willebrand factor associated with increased clearance (2005) (101)
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype (2008) (101)
Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes (1992) (98)
Pharmacokinetics and safety of fibrinogen concentrate (2009) (97)
Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation (1997) (97)
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. (2013) (94)
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype (1997) (92)
Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A (1996) (92)
Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. (1989) (91)
How I treat von Willebrand disease. (2009) (91)
How to estimate bleeding risk in mild bleeding disorders (2007) (91)
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia (2002) (86)
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. (2019) (85)
Evidence-based recommendations on the treatment of von Willebrand disease in Italy. (2009) (83)
Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues (2004) (82)
Bleeding scores in inherited bleeding disorders: clinical or research tools? (2008) (77)
Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease (1992) (77)
Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. (1991) (76)
Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families (2000) (76)
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. (2007) (75)
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study (2006) (73)
Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). (1999) (72)
Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) (1999) (71)
Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. (2008) (70)
Assessing bleeding in von Willebrand disease with bleeding score. (2007) (69)
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study (2009) (66)
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD) (2007) (64)
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V (1997) (64)
Deep intronic variations may cause mild hemophilia A (2011) (63)
Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis: Results From a Multicenter Study in 47 Patients (2004) (63)
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. (2014) (60)
Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A (2009) (58)
Clinical manifestations and management of Gaucher disease. (2015) (58)
Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A (2015) (57)
Bleeders, bleeding rates, and bleeding score (2013) (57)
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. (2015) (57)
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors (2012) (57)
Desmopressin for the treatment of haemophilia (2007) (56)
Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease (1995) (56)
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. (2019) (56)
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. (2003) (55)
The Factor VIII/Von Willebrand Factor Ratio Discriminates between Reduced Synthesis and Increased Clearance of Von Willebrand Factor (2002) (54)
Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. (1996) (54)
European retrospective study of real‐life haemophilia treatment (2017) (52)
Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations (2010) (52)
Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders (2017) (51)
Molecular diversity and thrombotic risk in protein S deficiency: The PROSIT study (2005) (50)
Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. (2011) (49)
Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect (2000) (48)
Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment. (2001) (48)
Hemophilia A and B: molecular and clinical similarities and differences (2019) (46)
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. (2015) (45)
How I treat type 2 variant forms of von Willebrand disease. (2015) (45)
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. (2019) (44)
Low prevalence of thrombophilia coagulation defects in patients with deep vein thrombosis of the upper limbs (1997) (44)
Characterization of two cases of acquired transitory von willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von willebrand factor (1995) (44)
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors (2019) (44)
The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease (1994) (43)
Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance (2011) (43)
Treatment of von Willebrand disease. (2005) (42)
TT virus contaminates first-generation recombinant factor VIII concentrates. (2001) (42)
The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD (2010) (42)
A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation (1996) (41)
The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH (2018) (41)
Pregnancy and delivery in women with von Willebrand disease (2019) (41)
Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance (2009) (41)
An Additional Unique Candidate Mutation (G2470A; M740I) in the Original Families with von Willebrand Disease Type 2 M Vicenza and the G3864A (R1205H) Mutation (2000) (40)
Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation (1990) (40)
Effectiveness of high‐dose intravenous immunoglobulin in a case of acquired von willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate (1992) (40)
Platelet von willebrand factor abnormalities in myeloproliferative syndromes (1995) (39)
Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency (1996) (39)
Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor (1988) (39)
Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system. (1998) (38)
Gestational thrombocytopenia: a prospective study. (1997) (37)
A novel candidate mutation (Arg611→ His) in type I‘platelet discordant’von Willebrand's disease with desmopressin‐induced thrombocytopenia (1995) (37)
Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. (1989) (36)
A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3 (2007) (36)
Inhibitors in Hemophilia B (2018) (36)
Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery (2018) (36)
Platelet Adhesion to Collagen in Subtypes of Type I von Willebrand’s Disease Is Dependent on Platelet von Willebrand Factor (1990) (35)
Topologically equivalent mutations causing dysfunctional coagulation factors VII (294Ala-->Val) and X (334Ser-->Pro). (1994) (35)
Mutations in the erythropoietin receptor gene are not a common cause of Diamond-Blackfan anemia. (1996) (35)
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency (1996) (35)
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. (1990) (35)
Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease (2013) (34)
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. (2020) (34)
Acquired haemophilia: experience of two Italian centres with 17 new cases (1997) (34)
Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy (1987) (34)
High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. (1993) (33)
Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. (2008) (32)
Inhibitors in haemophilia B: the Italian experience (2013) (31)
Von Willebrand's disease: clinical management (2006) (31)
The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. (1994) (30)
Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A. (2014) (30)
Central nervous system bleeding in patients with rare bleeding disorders (2012) (30)
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation (2012) (30)
Clinical pharmacokinetics of a placenta‐derived factor XIII concentrate in type I and type II factor XIII deficiency (1991) (29)
The benefits of prophylaxis in patients with hemophilia B (2018) (29)
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect (2006) (29)
Acquired transitory von Willebrand syndrome with ciprofloxacin (1994) (29)
F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors (2007) (29)
A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. (1992) (29)
Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia (2002) (29)
Polycythemia vera and essential thrombocythemia in young patients. (1993) (29)
Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. (1990) (28)
Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians (2008) (27)
Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis (2014) (27)
Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura. (1992) (27)
von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels (2010) (27)
Acquired plasma factor XIII deficiencies. (1993) (26)
The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group. (1992) (26)
Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect (2008) (26)
Desmopressin and type II B von Willebrand disease (1996) (26)
Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis (2001) (26)
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. (2010) (26)
von Willebrand’s disease diagnosis and laboratory issues (2010) (26)
A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. (1998) (26)
Platelet von Willebrand factor assay: results using two methods for platelet lysis. (1990) (26)
Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease (2006) (26)
Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F (2000) (25)
Total Hip Arthroplasty in Haemophilic Patients with Modern Cementless Implants. (2015) (24)
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease (2013) (24)
Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (1997) (24)
ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854GIn, and the missense mutation Cys2362Phe. (2002) (24)
Hematological manifestations and complications of Gaucher disease (2016) (24)
Association of factor V deficiency with factor V HR2. (2004) (23)
Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo‐ and afibrinogenemia (2009) (23)
F8 mRNA studies in haemophilia A patients with different splice site mutations (2010) (23)
Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. (2009) (23)
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. (2019) (22)
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A (2006) (22)
Missense or splicing mutation? The case of a fibrinogen Bbeta-chain mutation causing severe hypofibrinogenemia. (2004) (22)
Multimeric pattern of plasma and platelet von willebrand factor is normal in uremic patients (1993) (22)
Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders (2019) (22)
Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies (2010) (21)
Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. (1993) (21)
Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype (2010) (21)
Congenital afibrinogenemia: Successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive (1995) (21)
Inherited abnormalities of blood coagulation in juvenile stroke. A case‐control study (1997) (21)
Treatment of von Willebrand disease with FVIII/VWF concentrates. (2011) (21)
Thrombosis in Subjects with Homozygous and Heterozygous Factor XII Deficiency (1992) (20)
Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. (1993) (20)
Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene (2007) (20)
Heterogeneity of Activated Protein C Resistance Phenotype in Subjects with Compound Heterozygosity for HR2 Haplotype and FV Leiden Mutation (R506Q) in Factor V Gene (2000) (20)
Ribosome readthrough accounts for secreted full‐length factor IX in hemophilia B patients with nonsense mutations (2012) (20)
Pseudo‐exon activation caused by a deep‐intronic mutation in the fibrinogen γ‐chain gene as a novel mechanism for congenital afibrinogenaemia (2007) (20)
The VITA Project: Heritability of Resistance to Activated Protein C (2000) (19)
The elusive pathogenesis of von Willebrand disease Vicenza. (2002) (19)
A comparison between two semi‐quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease (2011) (19)
Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks (2018) (18)
Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia. (1993) (18)
Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. (2002) (18)
Fibrinolytic studies in 13 unrelated families with factor XII deficiency. (1991) (18)
Reduced von Willebrand factor secretion is associated with loss of Weibel–Palade body formation (2012) (18)
A type II mutation (Glu117stop), induction of allele-specific mRNA degradation and factor XI deficiency. (2005) (18)
High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura. (1996) (18)
Recombinant FXIII (rFXIII-A 2 ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency (2018) (18)
No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance (2015) (18)
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain (1995) (17)
Von Willebrand Disease: Epidemiology (2007) (17)
Identification and computationally‐based structural interpretation of naturally occurring variants of human protein C (2007) (17)
Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease (2005) (17)
Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B (2019) (17)
Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381 → Ser) in the substrate‐binding pocket (1993) (17)
Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blasts. (1993) (16)
Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality (2016) (16)
VON WILLEBRAND FACTOR ABNORMALITIES IN TWO PATIENTS WITH URAEMIA (1988) (16)
A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. (2002) (16)
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations. (2017) (16)
Desmopressin‐induced thrombocytopenia in type i platelet discordant von willebrand disease (1993) (15)
The spectrum of factor XI deficiency in Italy (2014) (15)
Characterization of the neutralizing anti‐emicizumab antibody in a patient with hemophilia A and inhibitor (2020) (15)
Management of thrombocytopenia in cancer. (2018) (15)
Coinheritance of the HR 2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R 506 Q ( Factor V Leiden ) (1999) (15)
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study (2020) (15)
Hemophilia A and B: molecular and clinical characteristics of similar, but different diseases. (2019) (14)
Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population (2018) (14)
The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency (2000) (14)
Novel Y283C mutation of the A subunit for coagulation factor XIII: molecular modelling predicts its impaired protein folding and dimer formation (2001) (14)
Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures. (2017) (14)
EDTA‐dependent pseudothrombocytopenia (1992) (14)
Prevalence of type 2b ‘Malmö/New York’ von Willebrand disease in Italy: the role of von Willebrand factor gene conversion (2008) (14)
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates (2019) (14)
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis (1999) (14)
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET (2020) (14)
Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A (2016) (13)
Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura. (1991) (13)
Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation (2000) (13)
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. (2013) (13)
A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. (1992) (13)
Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: Definite evidence for the non‐penetrance of the C2362F mutation (2007) (13)
Blood group significantly influences von Willebrand factor increase and half‐life after desmopressin in von Willebrand disease Vicenza (2010) (12)
Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method (1993) (12)
Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. (1993) (12)
A proteomic analysis of changes in prothrombin and plasma proteins associated with the G20210A mutation (2004) (12)
Immunophenotypic and genotypic characterization of B-cell chronic lymphocytic leukemia patients from northern Italy. (1993) (12)
Bβ 14 Arg→Cys variant dysfibrinogen and its association with thrombosis (2005) (12)
The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors. (2017) (12)
Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B (2019) (11)
Effect of the VWF promoter (GT)n repeat and single‐nucleotide polymorphism c.‐2527G>A on circulating von Willebrand factor levels under normal conditions (2011) (11)
High rate of sustained virological response with direct‐acting antivirals in haemophiliacs with HCV infection: A multicenter study (2019) (11)
TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A (2019) (11)
The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology (2021) (11)
Advances in the diagnosis and management of type 1 von Willebrand disease (2011) (11)
New development in von Willebrand disease (2013) (11)
Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres (2015) (10)
The Genetic Defect of Type I von Willebrand Disease “Vicenza” Is Linked to the von Willebrand Factor Gene (1993) (10)
An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study (2018) (10)
Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown (2018) (10)
Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A‐LONG and Kids A‐LONG Studies (2017) (10)
Multiplex Amplification and Fluorimetric Detection of Short Tandem Repeats for Mixed Chimerism After Bone Marrow Transplant (2003) (10)
The factor VIII treatment history of non‐severe hemophilia A (2020) (10)
Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients. (2007) (10)
Thrombin potential and traditional coagulation assay: are they useful in exploring recurrent pregnancy loss risk? (2017) (9)
A new Italian family with severe prekallikrein deficiency. Desmopressin-induced fibrinolysis and coagulation changes in homozygous and heterozygous members (1990) (9)
A novel G-to-A mutation in the intron-N of the protein S gene leading to abnormal RNA splicing in a patient with protein S deficiency. (2003) (9)
Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors (2021) (9)
Congenital hypofibrinogenemia associated with novel heterozygous fibrinogen Bβ and γ chain mutations (2008) (9)
Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors). (2016) (9)
Molecular characterization of five Italian families with inherited severe factor XIII deficiency (2007) (9)
Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? (1993) (9)
Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE) (2018) (9)
Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy (1989) (9)
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. (2022) (9)
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A (2016) (9)
Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis. (2018) (9)
First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies (2020) (9)
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence (2020) (9)
Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia. (1992) (9)
Thrombosis in Patients with Heterozygous and Homozygous Factor XII Deficiency Is not Explained by the Associated Presence of Factor V Leiden (1996) (9)
Congenital hypofibrinogenemia associated with novel homozygous fibrinogen Aα and heterozygous Bβ chain mutations. (2015) (9)
Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017) (9)
Erythema multiforme after intravenous immunoglobulin (1988) (8)
von Willebrand factor multimers von Willebrand disease "Vicenza" with larger-than-normal (supranormal) (2011) (8)
Pulmonary embolism after pregnancy in a patient with polycythemia vera (2001) (8)
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre (2020) (8)
One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B (2019) (8)
B cell–activating factor modulates the factor VIII immune response in hemophilia A (2021) (8)
Angiodysplasia and von Willebrand’s Disease (1994) (8)
Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas (2011) (8)
New approaches in the measurement of coagulation (2008) (8)
Autosomal Recessive von Willebrand Disease Type 1 or 2 due to Homozygous or Compound Heterozygous Mutations in the von Willebrand Factor Gene (2009) (8)
Successful use of recombinant FVIIa in combined factor V and FVIII deficiency with surgical bleeding resistant to substitutive treatment. A case report (2011) (8)
A contribution to the pathology of acquired plasma factor XIII deficiency. (1985) (8)
Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency (2012) (8)
AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years (2020) (7)
Adult patients with the nephrotic syndrome: really at high risk for deep venous thromboembolism? Report of a series and review of the literature. (1993) (7)
Viscosupplementation in symptomatic haemophilic arthropathy of the knee and ankle: Experience with a high molecular weight hyaluronic acid (2020) (7)
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation (1998) (7)
The response of plasma von Willebrand factor to desmopressin (DDAVP) is related to the platelet levels of von Willebrand factor. (1992) (7)
Calibration of Lyophilized Standards for Ristocetin Cofactor Activity of von Willebrand Factor (vWF) Requires vWF-Deficient Plasma as Diluent for Dose-Response Curves (1987) (7)
Association of protein S p.Pro667Pro dimorphism with plasma protein S levels in normal individuals and patients with inherited protein S deficiency. (2007) (7)
The Epidemiology of von Willebrand Disease (2011) (7)
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A (2021) (7)
A novel factor XI missense mutation (Val371Ile) in the activation loop is responsible for a case of mild type II factor XI deficiency (2007) (6)
Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. (2016) (6)
Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method. (1993) (6)
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls (2018) (6)
Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B (2016) (6)
Hemophilia management: Huge impact of a tiny difference (2020) (6)
Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy (2018) (6)
Is a reduced intensity treatment with Rituximab effective in acquired haemophilia A? (2011) (6)
Flow cytometry in the diagnosis of drug‐induced thrombocytopenia: Two illustrative cases (2008) (6)
First Italian Families with Homozygous R854Q Type 2 N Von Willebrand Disease (2002) (6)
Fibrinogen Vicenza and Genova II: Two New Cases of Congenital Dysfibrinogenemia with Isolated Defect of Fibrin Monomer Polymerization and Inhibitory Activity on Normal Coagulation (1987) (6)
In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma. (1992) (6)
Acquired transitory factor XI inhibitor after gynaecological surgery (2008) (6)
Fulminant sepsis in adults splenectomized for Hodgkin's disease. (1993) (5)
Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 (2019) (5)
Phase 2b Trial of AMT-061 (AAV5-Padua hFIX): Translation into Humans of an Enhanced Gene Transfer Vector for Adults with Severe or Moderate-severe Hemophilia B (2019) (5)
Grossly Abnormal Proteolysis of von Willebrand Factor (VWF) in a Patient Heterozygous for a Gene Deletion and Mutation in the Dimerization Area of VWF (2000) (5)
Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study (2021) (5)
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains. (2020) (5)
Severe factor XI deficiency in the Abruzzo region of Italy is associated to different FXI gene mutations (2008) (5)
How I treat von Willebrand disease. (2020) (5)
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. (1993) (5)
Current and emerging biologics for the treatment of hemophilia (2019) (5)
Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial (2020) (4)
The bleeding phenotype in people with nonsevere hemophilia (2022) (4)
Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives (2021) (4)
Factor XI gene mutations in factor XI deficient patients of the Czech Republic (2008) (4)
[Prevention of hemorrhage and dental treatment of patients with congenital or acquired coagulopathies]. (1997) (4)
The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study (2019) (4)
An unusually prolonged case of heparin-induced thrombocytopenia and disseminated intravascular coagulation. (1992) (4)
Recurrence of the ‘deep-intronic’ FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto (2009) (4)
The von Willebrand factor (1990) (4)
Successful treatment of neonatal "autoimmune" thrombocytopenia with high-dose intravenous immunoglobulins. (1985) (4)
Subunit Composition of Plasma von Willebrand Factor (vWF) in Two Uremic Patients with Acquired vWF Abnormalities (1992) (4)
Triton X contaminating platelet lysate critically affects the measurement of von Willebrand factor ristocetin cofactor activity. (1989) (4)
Low bone mass and hypovitaminosis D in haemophilia: A single‐centre study in patients with severe and moderate haemophilia A and B (2020) (4)
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors (2021) (4)
Effect of DCEP Mobilizing Regimen in in vivo Purging of PBSC Harvests in Multiple Myeloma (2004) (4)
The Italian institutional accreditation model for Haemophilia Centres. (2014) (4)
Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model (2018) (3)
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2021) (3)
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study (2022) (3)
The Ser460Pro substitution of the protein S (PS) gene in rare in Italian patients with type IIa PS deficiency. (1996) (3)
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes (2021) (3)
Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A (2018) (3)
The Coagulopathy of Acute Leukemia (1992) (3)
Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy. (2015) (3)
Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A (1989) (3)
Recurrent life-threatening epistaxis in a child with Bernard-Soulier syndrome controlled by bilateral ligation of external carotids and ethmoidal arteries. (1987) (3)
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy (2022) (3)
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors (2022) (3)
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study (2020) (3)
Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. (2022) (3)
Chapter 6. Von Willebrand Disease (2007) (3)
A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F Mutation). (2008) (3)
Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency (2009) (3)
One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates (1985) (3)
Diagnosis and management of von Willebrand disease in Italy (2018) (3)
von Willebrand disease and von Willebrand factor (2022) (3)
ERYTHROCYTE FRAGMENTATION IN DISSEMINATED INTRAVASCULAR COAGULATION (DIC) IN ACUTE LEUKAEMIA (1985) (3)
The higher prevalence of missense mutations in hemophilia B compared to hemophilia A could be important in determining a milder clinical phenotype in patients with severe hemophilia B (2016) (3)
Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients (2019) (2)
Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients (2022) (2)
Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence (2022) (2)
Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis (2021) (2)
Erratum: Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy (Blood Transfusion (2014) 12 (575-98)) (2015) (2)
Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies (2019) (2)
Short and Long-Term Outcomes in Hemophilia Patients with Inhibitors Undergoing Orthopedic Prosthetic Surgery (2015) (2)
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians (2021) (2)
Pharmacokinetic Evaluation of a Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency. (2008) (2)
Histidine-rich glycoprotein changes during pregnancy in a woman with genetically transmitted high levels of the protein and thrombotic diathesis. (1993) (2)
Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy (2017) (2)
Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia. (1989) (2)
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients: a reply to a rebuttal (2012) (2)
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial (2019) (2)
A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency (2013) (2)
Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A (2013) (2)
Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies (2015) (2)
Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients (2013) (2)
Platelet ristocetin cofactor (RiCof) in patients with type I "platelet normal" von Willebrand disease correlates with plasma RiCof peak after desmopressin infusion. (1995) (2)
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study (2022) (2)
2B or not 2B: when VWF is not a good platelet friend. (2013) (2)
No Influence of Blood Group on the Responsiveness to Desmopressin in Type I “Platelet Normal” von Willebrand’s Disease (1995) (2)
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors (2021) (2)
Ex vivo experimental thrombosis in variants of von Willebrand disease. (1993) (2)
Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D9-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study (2012) (2)
A novel G-toA mutation in intron-N of the protein S gene leading to abnormal RNA splicing in a patient with protein S deficiency (2003) (2)
Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera. (2006) (2)
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (2023) (2)
Hemophilia A: different phenotypes may be explained by multiple and variable effects of the causative mutation in the F8 gene (2018) (2)
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY) (2022) (2)
TREATMENT OF DIC ASSOCIATED WITH APL. RESPONSE (1990) (1)
The Management of the Haemophilic Arthropathy (2017) (1)
PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS (2019) (1)
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors (2022) (1)
Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up (2022) (1)
Inhibitor development: The last enemy to be defeated in hemophilia A and B (2014) (1)
Two families with combined homozygous/heterozygous factor V Leiden mutation and heterozygous G20210A factor II variant. (2000) (1)
Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study (2019) (1)
ON THE DISCREPANT POST‐DDAVP INCREASE OF FVIII:C AND VON WILLEBRAND FACTOR IN SOME PATIENTS WITH SEVERE VON WILLEBRAND'S DISEASE (1995) (1)
A novel fibrinogen gamma chain mutation (gamma 239 Gln-->His) is the cause of dysfibrinogenemia Vicenza. (2005) (1)
Outcome in moderate haemophilia: back to the past? Remarks on haemophilia A classification and treatment. (2014) (1)
A type mutation II (Glu117stop), induction of allele-specific mRNA degradation and FXI deficiency (2005) (1)
On the Use of Desmopressin in von Willebrand Disease (2011) (1)
Fibrinogen survival and fibrinopeptide A in acute leukemia. (1993) (1)
Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial (2021) (1)
Vonicog alfa for the treatment of von Willebrand disease (2016) (1)
A novel fibrinogen γ chain mutation (γ 239 Gln→His) is the cause of dysfibrinogenemia Vicenza (2005) (1)
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results (2022) (1)
A core set of outcome measurement tools in patients with hemophilia A systematic review of the measurement properties (1)
Pathogenesis of the Haemophilic Arthropathy (2017) (1)
Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia (2021) (1)
treatment in mild hemophilia A Molecular and clinical predictors of inhibitor risk and its prevention and (2014) (1)
Chapter 8. Von Willebrand Disease (2010) (1)
Advances in diagnosis of von Willebrand disease (2019) (1)
Current Management of von Willebrand’s Disease (1995) (1)
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe (2022) (1)
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study (2022) (1)
Juvenile essential thrombocythemia: really a benign disease? (1989) (1)
Management of Spontaneous Bleeding and Prevention of Bleeding After Dental Extractions and Other Surgical Procedures in Mild Hemophilia a and Von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center (1993) (1)
Non-Compartment and Compartmental Pharmacokinetics, Efficacy, and Safety of Kedrion FIX concentrate. (2020) (1)
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. (2022) (1)
BLEEDING TIME IN NORMAL SUBJECTS: ITS RELATIONSHIP WITH SEX, AGE, BLOOD GROUP, HEMATOCRIT, PLATELET COUNT AND PLASMA VON WILLEBRAND FACTOR LEVEL (1987) (1)
Idelvion For The Treatment of Hemophilia B: A Budget Impact Analysis In The Italian Setting (2017) (1)
[Therapy with high-dose intravenous gamma globulin in the newborn infant with thrombocytopenia from passive immunization]. (1985) (1)
A new case of passovoy defect (1992) (1)
In fl uence of proband ’ s characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G 20210 A polymorphisms (2013) (1)
Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia (1989) (1)
Determinants of inhibitor development in previously treated hemophilia A patients (2015) (1)
European Study MCMDM-1VWD phenotype in type 1 von Willebrand disease (VWD): results from the Response to desmopressin is influenced by the genotype and (2013) (1)
The Arrival of Gene Therapy for Patients with Hemophilia A (2022) (1)
AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirms Stable FIX Expression and Sustained Reductions in Bleeding for up to 5 Years (2021) (1)
Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long‐term prophylaxis: An expert opinion paper from an Italian panel (2022) (1)
[Tooth extractions in patients with hemophilia and von Willebrand's disease]. (1987) (0)
Preliminary characterization of a new congenital hypodysfibrinogenemia (vicenza II) and of dysfibrinogenemia genova IV (1993) (0)
THROMBOSIS AND HEMOSTASIS Speci ﬁ c factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations (2017) (0)
Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age (2021) (0)
PF802 ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L (2019) (0)
Eight novel mutations in FXI gene (2005) (0)
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A (2021) (0)
Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease (2015) (0)
S297: ASSESSING THE COST-EFFECTIVENESS OF LONG-TERM PROPHYLAXIS STRATEGIES IN VON WILLEBRAND DISEASE (2022) (0)
Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study (2022) (0)
Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial (2020) (0)
Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project (2018) (0)
Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project) (2018) (0)
THROMBOSIS AND HEMOSTASIS VWF propeptide and ratios between VWF , VWF propeptide , and FVIII in the characterization of type 1 von Willebrand disease (2013) (0)
thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential (2013) (0)
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms (2022) (0)
Type II mutation (Glu117stop) causes factor XI deficiency by inducing allele specific mRNA degradation (2005) (0)
A Two-Year Prospective Study on Bleeding Tendency In 105 Patients with Type 2 A and M Von Willebrand Disease (2010) (0)
OPINION New development in von Willebrand disease (2013) (0)
Ongoing developments in our understanding of haemophilia - perspectives on the therapeutic and immunogenic potential of Factor VIII (Il Ciocco - Barga (LU), 5-6 June 2015). (2015) (0)
Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study (2022) (0)
Von Willebrand disease: 80 year-old without wrinklesl (2009) (0)
Fall Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients (1993) (0)
Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications (2022) (0)
A contribution to the debate about the possible different clinical severity between hemophilia A and B (2016) (0)
[Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease] (2016) (0)
Aspects of clearance of VWF (2015) (0)
Factors VIII and Von Willebrand Levels in Women Undergoing Assisted Reproduction: Are Their Levels Associated with Clinical Pregnancy Outcome? (2020) (0)
1 SPECIFIC FACTOR IX mRNA and PROTEIN FEATURES FAVOR DRUG-INDUCED READTHROUGH OVER RECURRENT NONSENSE MUTATIONS Short title : Determinants of drug-induced readthrough in HB (2017) (0)
Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis (2014) (0)
von Willebrand's disease and hemophilia A Consistency of responses to repeated DDAVP infusions in patients with (2011) (0)
THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A (2013) (0)
Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the in-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project (1993) (0)
New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A (2022) (0)
Pain relief with Eptacog beta in haemophilia patients with inhibitors (2023) (0)
Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry (2021) (0)
Authors' reply (1994) (0)
Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A (2023) (0)
Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. (2018) (0)
RISE: Response to DDAVP In mild Hemophilia A patients: in Search for dEterminants (2013) (0)
Women with rare bleeding disorders (2008) (0)
Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study (2015) (0)
Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients (2010) (0)
cause of Diamond-Blackfan anemia Mutations in the erythropoietin receptor gene are not a common (2011) (0)
Brief report Missense or splicing mutation? The case of a ﬁbrinogen B (cid:1) -chain mutation causing severe hypoﬁbrinogenemia (2004) (0)
Von Willebrand Disease: Clinical Aspects and Practical Management (2014) (0)
PRO40 Cost-Consequence Analysis of Emicizumab Prophylaxis for Severe Hemophilia a Patients without Inhibitors (2020) (0)
THROMBOSIS AND HEMOSTASIS Hemostatic ef ﬁ cacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease (2016) (0)
Clinical presentation of inhibitor development in non-severe hemophilia A: Half of patients have high titer inhibitors and present with bleeding complications (2014) (0)
HOPE-B: Study Design of a Phase III trial of an Investigational Gene Therapy AMT-061 in Subjects with Severe or Moderately Severe Hemophilia B (2019) (0)
The International Classification of Functioning as a framework for development of a core set of musculoskeletal measures in hemophilia (2015) (0)
FIBRINOGEN GENOVA III: A NEW CONGENITAL DYSFIBRINOGENEMIA WITH BLEEDING DIATHESIS AND DEFECTIVE LYSIS BY PLASMIN (1987) (0)
The POWER app: design and usability testing of a mobile app for the collection of patient-reported outcome data in type A haemophilia (Preprint) (2020) (0)
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors (2022) (0)
HOMOZYGOUS FACTOR XII CONGENITAL DEFICIENCY: STUDY OF 10 NEW FAMILIES. (1987) (0)
0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation (2011) (0)
Intrinsic and method-induced variation of the bleeding time and related parameters (2007) (0)
Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting (2022) (0)
Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association (2022) (0)
Genetically defined protein S (PS) deficiency is associated with venous thrombosis (2003) (0)
Reply to: [Factor XI mutation and the origin of Ashkenazi Jews. Haematologica 2008; 93:e59] (2008) (0)
Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs (2023) (0)
Reduced Von Willebrand Factor Secretion Is Associated with Loss of Weibel-Palade Formation (2010) (0)
How I treat How I treat von Willebrand disease (2009) (0)
Von Willebrand disease : 80 year-old without wrinkles (2007) (0)
Clinical, economic, and health‐related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews (2022) (0)
SAT0648 Coxalgia in hemophilic patients. sonographic evaluation of a not target joint (2018) (0)
P69. Porcine factor VIII by continuous infusion in patients with haemophilia A and inhibitors (1996) (0)
The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both (2000) (0)
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience (2023) (0)
Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post hoc analysis from a phase 3 trial. (2023) (0)
Comment on Casari et al , page 2893 2 B or not 2 B : when VWF is not a good platelet friend (2013) (0)
Factor XIII deficiency type I: some unresolved issues (1992) (0)
A Poor Response to Desmopressin Is Observed in Patients with Mild Hemophilia a and No Detectable FVIII Mutation. (2008) (0)
Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients (2013) (0)
von Willebrand Disease "Vicenza" With Larger-Than-Normal (Supranormal) von (2016) (0)
Von Willebrand Factor antigen and age explain variation in baseline FVIII: C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser) (2014) (0)
Type 2B “Malmo/New York” Is Not So Rare among Italian Patients with von Willebrand Disease: The Role of P1266L/Q Mutations of the von Willebrand Factor Gene in Seven Cases. (2007) (0)
Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial (2016) (0)
Inherited thrombophilic syndromes: Experience of a department of hematology (1993) (0)
Abstract (2003) (0)
Comparison of von Willebrand factor platelet‐binding activity assays: ELISA overreads type 2B with loss of HMW multimers (2020) (0)
In-vitro expression and functional characterization of four mutations causing factor XI deficiency (2005) (0)
Multicenter Evaluation of a New Concentrated Desmopressin Preparation (Emosint) Administered Intravenously or Subcutaneously: Analysis of Biological Responses and Side-Effects in 49 Patients with Hemophilia a and Von Willebrand’s Disease (1993) (0)
disease Epidemiological investigation of the prevalence of von Willebrand's (2011) (0)
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study (2022) (0)
Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up (2023) (0)
PROSPECTIVE STUDY OF THE IMMUNOLOGICAL MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS WITH INHIBITORS (2017) (0)
PRO53 Economic IMPACT of Emicizumab Prophylaxis for Hemophilia a with and without Inhibitors (2020) (0)
Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. (2009) (0)
theorem approach Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes (2009) (0)
A BAYESIAN APPROACH TO THE DIAGNOSIS OF TYPE 1 VON WILLEBRAND DISEASE (2007) (0)
F8 Gene Mutations and ITT Response in the Italian Cohort of Haemophilia A Patients with Inhibitors. (2005) (0)
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2023) (0)
Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors (2022) (0)
Desmopressin-induced thrombocytopenia in von Willebrand disease patients with the Arg611His mutation in the A1 domain of von Willebrand factor. (1996) (0)
Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B (2023) (0)
von Willebrand Factor: A Prima Ballerina on Two Different Stages P.M. Mannucci New Perspectives on von Willebrand Factor Functions in Hemostasis and Thrombosis (2005) (0)
CLINICAL AND MOLECULAR PREDICTORS OF THROMBOCYTOPENIA AND RISK OF BLEEDING IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 2B: A COHORT STUDY OF 67 PATIENTS Running title: Thrombocytopenia and bleeding risk in VWD 2B (2008) (0)
Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study (2018) (0)
First factor IX mutations in Albanian hemophilia B patients (2008) (0)
pa-Clinical manifestations and management of Gaucher disease (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giancarlo Castaman?

Giancarlo Castaman is affiliated with the following schools: